Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency
Investigational Products: Niraparib Period: 3 years after IRB/EC approval Indication: Adult patients with histologically confirmed and locally advanced, unresectable, or metastatic solid tumors having known or suspected deleterious mutations in genes involved in homologous recombination repair (HRR) or homologous recombination deficiency identified by whole genome sequencing
Efficacy
DRUG: Niraparib
objective response after 8 weeks, Antitumor activity defined as objective response after 8 weeks, at 8 weeks after Cycle 1 Day 1(each cycle is 28 days)
Objectives:

1. Primary Objective

   - Antitumor activity defined as objective response at ≥ 8 weeks or stable disease (SD) at ≥ 16 weeks from the time of enrollment.
2. Secondary Objectives

   * Overall Survival (OS)
   * Progression-Free Survival (PFS)
   * Objective Response Rate (ORR) by RECIST v1.1
   * Duration of response (DOR)
   * Quality of life (QOL) assessed by EORTC-QLQ-C30
   * Adverse Event (AEs)
   * Exploratory biomarker analyses